Cardiol Therapeutics (CRDL) Research & Development (2020 - 2026)

Cardiol Therapeutics has reported Research & Development for 7 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 37.83% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.0 million (up 6.26% YoY), and the FY2025 full-year result was $10.1 million, changed 0.22% from the prior year.
• Research & Development for Q1 2026 stood at $3.6 million, up from $2.0 million in the prior quarter.
• The five-year high for Research & Development was $4.1 million in Q4 2022, with the low at $1.9 million in Q3 2023.
• Historically, Research & Development has averaged $2.9 million across 5 years, with a median of $3.0 million in 2023.
• Annual changes were most pronounced in 2022 — Research & Development surged 105.1% — and 2023, when it plunged 50.74%.
• Cardiol Therapeutics' Research & Development stood at $4.1 million in 2022, then retreated by 28.29% to $3.0 million in 2023, then climbed by 2.0% to $3.0 million in 2024, then slumped by 35.03% to $2.0 million in 2025, then surged by 83.5% to $3.6 million in 2026.
• The last three Research & Development figures came in at $3.6 million (Q1 2026), $2.0 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.